|
AU2007242957A1
|
|
Human elongase genes and uses thereof
|
|
WO2004043999A2
|
|
Hsan ii related gene and expression products and uses thereof
|
|
WO2004003159A2
|
|
Novel therapeutic target for treating vascular diseases, dyslipidemias and related disorders
|
|
WO03035691A1
|
|
Apolipoprotein a-i mutation useful for diagnosis and treatment of cardiovascular diseases
|
|
AU2002324856A1
|
|
High throughput screening assays using fatty acid synthetic enzymes
|
|
WO03004045A2
|
|
Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
|
|
WO03005034A2
|
|
Processes for identifying therapeutic agents useful in treating diseases involving fzd4 gene
|
|
AU2002317093A1
|
|
Screening processes for agents modulating cholesterol levels
|
|
EP1397385A2
|
|
Methods for treating disorders of the nervous and reproductive systems
|
|
WO02097123A2
|
|
Diagnostic methods for cardiovascular disease, low hdl-cholesterol levels, and high triglyceride levels
|
|
WO02084301A2
|
|
Screening assay for agents modulating activity of the abca1 protein
|
|
AU2140402A
|
|
Human elongase genes uses thereof and compounds for modulating same
|
|
CA2429455A1
|
|
Fat regulated genes, uses thereof, and compounds for modulating same
|
|
CA2427024A1
|
|
Methods for screening compounds that modulate lipid metabolism
|
|
AU2001289457A8
|
|
Methods and compositions employing a novel stearoyl-coa desaturase-hscd5
|
|
CA2398940A1
|
|
Methods and compositions using stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
|
